Efficacy of injectable transamine in patients with benign prostatic hyperplasia

Phase 2

Recruiting

• Conditions: Benign prostate enlargement.; Benign neoplasm of prostate; D29.1

• Registration Number: IRCT20211121053127N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Patients undergoing Prostatectomy
Patients who are willing to participate in the study

Exclusion Criteria

Use of anticoagulants such as aspirin and dipyridamole
Prothrombin time and partial thromboplastin time are high for whatever reason
Any history of thrombotic events
History of bleeding disorders
Chronic kidney disease (serum creatinine greater than 180 micromoles per liter).

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bleeding volume. Timepoint: 24 hours after surgery. Method of measurement: The amount of ml of blood removed from the patient's body.